Scleraxis is a transcription factor expressed during early periods of mouse tendon morphogenesis. We have determined that tendon is first clearly present in mouse limb at embryonic day 14.5 (E14.5) and, by in situ hybridization, that scleraxis is expressed in the mouse tendons at E14.5. We have also investigated the regulatory elements that direct scleraxis gene expression to the limb tendons. DNA constructs were engineered such that the lacZ reporter gene was expressed under the control of portions of scleraxis regulatory regions. Transgenic mice carrying these constructs were made and expression of the construct was monitored by staining for b-galactosidase activity. A construct containing 7 Kbp of 5 0 flanking sequence, the intron, both exons and 1.8 Kbp of 3 0 flanking sequence was expressed in a pattern that closely resembled the endogenous scleraxis gene. Mouse embryos carrying this construct expressed lacZ in their limb flexor and extensor tendons at E14.5. The lacZ stain in tendon was readily distinguished from -muscle using an anti-myosin heavy chain antibody to visualize muscle. Deletion of the intron, exons and 3 0 flanking region did not affect the pattern of tendon expression in the limbs of E14.5 transgenic mice.
Introduction
Tendon is a dense collagenous tissue composed of extracellular matrix (ECM) molecules secreted by tendon fibroblasts. The role of tendon is to transmit force exerted by muscle to the point where it inserts into bone. Studies of tendon as a tissue have focussed on its structure, biochemical composition, and material properties. Tendon development has been studied from an anatomical and morphological point of view mainly in the chick limb (Hurle et al., 1990; Ros et al., 1995; Kardon, 1998) , with a few other reports on rat, and bovine tendon (Greenlee and Ross, 1967; Evanko and Vogel, 1990) . Most studies of tendon development have focussed on the questions of whether muscle and tendon are derived from the same cell precursors, and whether muscle is necessary for tendon development. Chick/quail transplantation experiments have made it clear that the connective tissue of the chick limb is derived from the somatopleural mesenchyme, while the muscle cells are of somatic origin (Christ et al., 1977; Chevallier et al., 1977) . It has been demonstrated that initial differentiation of myogenic masses and formation of tendon primordia in the chick limb occur autonomously with respect to one another. However, later morphogenetic events do require reciprocal interactions between muscle and tendon (Kardon, 1998) .
Our long-term interest is to understand the molecular mechanisms underlying tendon development. Transcription factors that are tissue or cell specific are mainly controlled at the level of transcription through regulatory elements in their promoters (Krumlauf, 1994; Molkentin and Olson, 1996) . Therefore, we decided to seek a transcription factor that is expressed in the mouse during early stages of tendon development and then analyze the whole genomic locus to identify cis-regulatory elements responsible for tendon expression.
In the last few years, several transcription factors that are expressed in tendon have been described. Among these are Scx, Six1, Six2, Eya1 and Eya2 (Cserjesi et al., 1995; Oliver et al., 1995; Xu et al., 1997) . We have focussed our analysis on the Scleraxis (Scx) gene. Scx is a basic helix -loop -helix (bHLH) transcription factor first identified in mouse as a heterodimeric partner of the ubiquitous bHLH transcription factor E12. Scleraxis has been shown to be expressed in the sclerotomal compartment of the somites that give rise to ribs and vertebrae and in mesenchymal precursors of axial, appendicular and craniofacial skeletal elements. It was also expressed in cells of tendons and ligaments (Cserjesi et al., 1995) . Several studies have shown a temporal and spatial association of scleraxis (Scx) expression with tendon development (Schweitzer et al., 2001; Edom-Vovard et al., 2002; Asou et al., 2002) .
As an initial step in developing tools that will help us address the molecular mechanisms of tendon development, we have characterized the genomic organization of Scx and sequenced an 11 Kbp genomic clone of the mouse Scx gene. The whole genomic locus has been analyzed for the presence of a tendon enhancer element(s) using lacZ as a reporter gene in transgenic mice. We show that lacZ tendon expression is maintained when the intron, exons and 1.8 Kbp of 3 0 flanking region are deleted. Further evidence suggests that the critical region responsible for tendon expression lies in155 bp located between 355 and 2 200 bp from the published cDNA sequence.
Results
2.1. Isolation, sequencing and characterization of the mouse genomic scleraxis gene
The Scx gene was determined to contain two exons and one intron (Fig. 1) . The position of the 895 bp intron was determined by PCR. The 5 0 splice donor and 3 0 acceptor sites of this intron conform to the GT/AG consensus. Exon 1 is at least 747 nucleotides in length. The exact length is uncertain because we were unable to identify the start site of transcription. Attempts were made to amplify the 5 0 end of the mRNA by RACE, but a full-length cDNA was not evident. Additional attempts to determine the 5 0 end of the mRNA by RNAse mapping and primer extension analysis were attempted, but without success. A blast search against the EST database was performed. There were no hits for scleraxis. Exon 2 is 350 bp in length containing 39 coding and 311 non-coding nucleotides. Two potential TATA boxes were found, one at 2 12 bp from the published cDNA, and another at 2 105. No apparent CAAT boxes were found. The polyadenylation signal is AAUUAAA and it is located 22 nucleotides upstream of the polyadenylation site. A total of approximately 11 Kbp of the mouse scx gene has been sequenced, including 2.2 Kbp of the gene itself, 1.8 Kbp of downstream sequence and 7 Kbp of upstream sequence. The sequence has been deposited in Genebank (Accession number: AY338482). Our sequence was compared with the scleraxis sequence available in the mouse Ensembl database. There is a perfect correlation between the sequences of the intron and second exon. However, the first exon from the mouse Ensembl database differs in several bases. The 5 0 -flanking region and the 3 0 -flanking region of the scleraxis gene were also compared. The mouse Ensembl sequence presents a couple of holes, one in the 5 0 flanking region and the other one in the 3 0 flanking region of the scleraxis gene. The rest of the sequence is highly accurate.
Expression of endogenous scleraxis in mouse tendons
Scx has been reported to be expressed in the sclerotome, cartilage and limbs of developing mouse embryos (Cserjesi et al., 1995; Brown et al., 1999) . Most importantly, scx is expressed in limb tendons of developing mouse embryos (Cserjesi et al., 1995; Schweitzer et al., 2001; Asou et al., 2002) and chick embryos (Edom-Vovard et al., 2002) .
There is a single descriptive paper about mouse tendon development (Milaire, 1963) . This study does not correlate days of embryogenesis with the stage of tendon development but rather describes stages of development according to the appearance of morphological structures. Therefore, it became important to verify when the tendon tissue would become morphologically apparent in limbs of mouse embryos by H&E stain. Although, limb cartilage was readily confirmed at E12.5, no tendon-like tissue could be identified at this stage. It was not until E14.5 that we were first able to find a tissue that had the appearance of tendon in the developing mouse limbs.
We analyzed the pattern of Scx expression in the developing limb tendons by in situ hybridization. Mouse embryo and limb sections from E11.5 to E15.5 were probed with a sense and an antisense Scx probe. At E11.5, scx was expressed around the precartilage masses of the axial skeleton, the limb mesenchyme and frontonasal mass. There was also expression in the tongue, lungs, and brain. At E12.5, Scx expression was around the ribs and adjacent to the intervertebral discs (data not shown). Also, Scx expression in this area had become more caudal. There was still expression in the tongue, lungs, and brain. In the limbs, Scx expression was found in mesenchymal masses (data not shown). From E13.5 onwards, we only analyzed limb sections. At E13.5 Scx was expressed in mesenchymal masses ( Fig. 2A) . At E14.5, the tendons that are clearly visible in the digits and the zeugopod showed hybridization with the Scx antisense probe (Fig. 2C,E) . At E15.5 Scx expression was still present in tendons (data not shown).
Scleraxis expression in transgenic mice
The full-length Scx/lacZ construct, contained 11 Kbp of the Scx locus and was engineered so that it contained from 7 Kbp of 5 0 flanking region of the Scx gene, both exons, the intron and 2.0 Kbp of downstream flanking region. A lacZ reporter gene was fused in frame 207 nucleotides downstream of the initiation codon of the Scx protein (Fig. 1B) . Expression of lacZ, driven by the whole Scx gene (Fig. 3) or by progressively smaller fragments of the gene (Fig. 4) was visualized by whole mount lacZ stain. Three independent transgenic founders containing the full-length Scx/lacZ 3 . Expression of the full-length Scx/LacZ transgene during mouse embryogenesis. Three transgenic lines carrying the full-length Scx/LacZ construct were generated. F 1 embryos were analyzed for b-galactosidase activity at different stages of development. At E10.5 and E11.5, lacZ expression is broad. E12.5, E13.5 and E14.5, lacZ staining becomes localized to the limbs, a small portion of the tail and the nose.
construct were used to establish lines. b-galactosidase activity of the transgene was monitored in embryos from E10.5 to E15.5 (Fig. 3) . The three lines all presented a similar pattern of expression. At E10.5 and E11.5, the lacZ pattern of expression appeared very broad. At E12.5, the lacZ pattern became restricted to the limbs, tail and the nose. At E13.5, the lacZ pattern was similar to E12.5 except that lacZ expression extended more distally in the limbs. At E14.5, the stain was more intense and it was even more distal in the limbs. The nose and tail continued to show lacZ expression. At E15.5, two of the lines presented lacZ expression with a similar spatial pattern as E14.5 (data not shown). The third showed no expression at E15.5.
Dissected limbs from E14.5 transgenic mice carrying the full-length Scx/lacZ construct showed dorsal and ventral b-galactosidase staining of tendons (Fig. 5 ). When these limbs were sectioned, blue tendons were apparent (Fig. 6A,B) . These tissue sections were also immunostained with an anti-myosin heavy chain antibody to show the location of muscle. The arrow in Fig. 6A shows a blue tendon running next to muscle tissue that is stained brown with the anti-myosin heavy chain antibody. The blue tendon does not overlap with the brown muscle, showing very clearly that they are different tissues and that Scx is expressed in tendon but not in muscle.
Overall, the pattern of lacZ expression using the 11 Kbp Scx DNA genomic fragment reproduced the endogenous Scx expression in the limbs as determined by in situ analysis in E11.5 -E15.5 embryos. However, the b-galactosidase pattern at E11.5 appeared to have a broader distribution in the rest of the body than the endogenous gene, indicating the lack of other regulatory elements. Most importantly, the elements that direct Scx expression to the limb tendons, were present in the 11 Kbp DNA fragment.
Expression of Scx/lacZ in transgenic mice carrying deletion constructs
In order to identify cis-acting regulatory regions that direct tendon-specific expression in limbs, constructs containing smaller genomic DNA fragments were made. These constructs were made using the Hsp68-lacZ reporter gene, which has a minimal promoter different than the endogenous Scx gene promoter. Fig. 1B shows the different constructs used to generate transgenic mice. The patterns of expression in E14.5 whole mount lacZ embryos carrying the different constructs are shown in Fig. 5 . Construct ZA10, which contained the whole 7 Kbp of 5 0 flanking region in front of the Hsp68-lacZ reporter gene, produced the same lacZ pattern of expression at E14.5 as the full-length Scx/lacZ construct (data not shown). Three E14.5 F o embryos were Fig. 4 . Whole mount lacZ stained E14.5transgenic embryos carrying the different constructs. Embryos carrying constructs full-length Scx/lacZ, ZBX6 and Z330 showed lacZ expression in the limb tendons, nose and tail. Embryo carrying the ZIS129 construct showed minimal lacZ expression in the limbs and tail and no expression in the nose. generated carrying the ZBX6 construct, which contains 500 bp of Scleraxis 5 0 flanking region. Tendon lacZ expression was observed in all three. In addition, three transgenic lines were generated with the ZBX6 construct. Two of the three lines produced the same developmental pattern of lacZ expression as the full-length Scx/lacZ construct between E10.5 and E14.5. The third line did not show any lacZ expression until E13.5 but the subsequent pattern of expression was similar to the other two lines. The pattern of expression of whole mount lacZ embryos carrying the ZBX6 construct at E14.5, compared to other constructs, is shown in Fig. 4 . LacZ expression was seen in the limbs, nose and tail. Fig. 5 shows ventral and dorsal views of dissected transgenic ZBX6 lacZ stained limbs at E14.5, compared to other constructs. Blue tendons were readily identified in sections of ZBX6 mouse limbs at E14.5 (Fig. 6 ). Fig. 6C shows a tendon that separates into smaller tendons in the hindlimb autopod. When these sections were immunostained with an anti-myosin heavy chain antibody, the blue b-galactosidase stain did not overlap with the brown muscle stain. Fig. 6D also shows lacZ expression in the interdigital area. showed the same lacZ pattern of expression at E14.5 as the previous constructs (Figs. 4, 5) . Eleven independent transgenic F o 's expressing lacZ at E14.5 were obtained. Also, seven independent F o 's expressing lacZ at E13.5 were examined. Interestingly, the lacZ pattern of expression of the E13.5 day embryos carrying the Z330 construct appeared in a broader area of the embryo than for the larger constructs (data not shown). Sections of Z330 transgenic limbs clearly showed tendon expression (Fig. 6E) . In contrast to all larger constructs, mice carrying the ZIS129 construct that has only 200 bp of 5 0 flanking region did not lacZ expression in the limb tendons at E14.5 (Figs. 4 -6 ). Eleven independent transgenic F o 's expressing lacZ were obtained. In five of the eleven embryos that were stained for lacZ, minimal or no expression was observed.
Sections from these limbs showed that none of the tendons stained blue (Fig. 6F ). In the other six embryos ectopic expression was observed.
Discussion
Because there has been only minimal study of mouse limb tendon development it was necessary to carry out an histological assessment to determine when tendons were first obvious. We conclude that limb tendons are first unequivocally present at E14.5 based on the presence of a tissue having cells aligned within a linearly organized fibrous structure. At earlier stages, the tendon primordia could not be identified by morphology alone. Staining with a human anti-tenascin antibody which does react with mouse did not help us identify early tendon primordia in the mouse limb, as has been reported in the chick (Kardon, 1998) . The anti-human tenascin antibody staining was not localized to mouse limb tendon until E16.5.
The transcription factor scleraxis was selected for this study because it was reported to be expressed in tendon during mouse development (Cserjesi et al., 1995) . Furthermore, recently Scx has been proposed as a tendon marker of tendons and tendon progenitors (Schweitzer et al., 2001 ). Expression of scleraxis had been identified in mouse embryogenesis as early as E3.5 (Brown et al., 1999) . There is an intricate and dynamic pattern of expression between E6.5 and E14.5, during which time the widespread expression becomes gradually restricted to the tendon (Cserjesi et al., 1995; Brown et al., 1999; Schweitzer et al., 2001) . Our in situ hybridization results are consistent with these reports, showing that between E11.5 and E13.5 Scx expression became more localized to mesenchymal masses in the limbs, presumably the pretendinous precursors of the appendicular skeleton. Specific tendon expression of Scx was present at E14.5, when tendon was first recognizable as a tissue, and continued at least until E15.5.
Transgenic mice carrying the full-length Scx/lacZ construct expressed lacZ in a pattern that closely reproduced the limb expression pattern of the endogenous Scx gene between E11.5 and E14.5. Both the transgene and the endogenous Scx had a broad pattern of expression in the rest of the body at E10.5. At E11.5, the endogenous gene became localized to mesenchymal masses of the appendicular skeleton and was also expressed in the tongue and frontonasal mass. However, the transgene at E11.5 still had a broader expression pattern in the rest of the body, suggesting a deletion of a repressive regulatory element. Only when the transgenic embryos reached E12.5 did the pattern of lacZ expression become more restricted in the rest of the embryo. Between E12.5 and E15.5 both the endogenous Scx and the transgene were expressed in the limbs, nose and tail. Although there was no apparent lacZ stain in tendons in parts of the embryo other than the limbs, we cannot say that the transgene was not expressed in tendons throughout the body because penetration of the stain is problematic in E14.5 embryos. This study was focussed on the limb tendons so we did not section transgenic embryos in order to determine whether there was expression in the rest of the body. Another difference between the endogenous and the transgene is that between E11.5 and E13.5 the endogenous gene was highly expressed in the pretendinous masses. For the transgene however, scleraxis expression from E12.5 to E15.5 appeared diminished, less intense. This could be an indication of other elements missing in the construct. Interestingly, the lacZ pattern of expression that we saw in tendon with all of our constructs reflected the endogenous pattern of expression in the zeugopod but did not recapitulate the endogenous gene expression in the more distal autopod, particularly there is lack of lacZ expression in the digits. The fact that the transgene was not able to fully recreate the pattern of expression of the endogenous gene is likely due to the lack of additional genomic sequences.
Deletions of the original Scleraxis construct indicated that loss of the 3 0 flanking region, the intron, and most of the 5 0 flanking sequence did not eliminate lacZ tendon expression in the zeugopod. A sequence of only 355 bp in length, upstream of the published cDNA scleraxis sequence, was able to direct tendon expression. However, when another 155 bp were deleted, so that only 200 bp were left upstream of the published cDNA sequence, there was no lacZ tendon expression. Taken together these observations may indicate that the sequences responsible for tendon expression may be contained in this 155 bp segment. Analysis of the critical 355 bp region in Scx indicates the presence of an E-box binding site. Scx has been shown to bind to an E-box sequence when it dimerizes with E12 (Cserjesi et al., 1995) . This opens the possibility that Scx might autoregulate itself. Several potentially interesting binding sites for other transcription factors are also present. For example, Sox5, which is involved in chondrogenesis (De Crombrugghe et al., 2000) , MyoD, MEF 2, and myogenin, which are involved in muscle differentiation (Lassar et al., 1989; Molkentin et al., 1995; Wright et al., 1989) . There is no information regarding the relevance or role of these factors in the regulation of Scx. However, such interaction of regulatory networks might be involved in coordinating the tendon, muscle, and cartilage attachments that give rise to the musculoskeletal system. In fact, there is evidence that suggests that Scx may have an effect in chondrogenesis. For example, overexpression of scleraxis in the Ros 17/2.8 osteosarcoma cell line increased expression of the cartilage markers (aggrecan and type II collagen), and suppressed expression of the osteoblast markers (type I collagen and alkaline phosphatase). As a result, bone cells took on characteristics more like cells of soft connective tissue. In addition, binding studies have shown that the aggrecan promoter contains a high-affinity binding site for Scx and can be transactivated by Scx in vitro (Liu et al., 1997) . The role of scleraxis in tendon development is not known. Unfortunately, the Scx null mutation did not shed light on its role in tendon because the mutation was lethal at such an early embryonic stage (Brown et al., 1999) , and tendon development was not addressed in the chimaeric rescue experiments done in the same study. However, tools are now available to perform more functional studies.
Experimental procedures
4.1. cDNA synthesis and probe synthesis cDNA was made using Thermoscript (Gibco, BRL). This cDNA was used as template to amplify a scx probe with primers ScleF1 5 0 -GTCGACCGCCGCCGCCGCCAC-CAC-3 0 and ScleR1 5 0 -GTCGACACTTGGCCCAGG-TAG-3 0 designed to produce a 405 bp fragment. PCR amplification was carried out for 30 cycles, with denaturation at 94 8C for 30 s, annealing at 60 8C for 30 s and elongation at 72 8C for 30 s. The amplified fragment was sequenced to verify that it was derived from the Scx gene. The fragment was radiolabeled with 32 P and used to screen a mouse genomic library.
DNA isolation, sequencing and analysis of the mouse genomic scleraxis clone
A mouse sCos-1 genomic library derived from a 129 strain embryonic stem cell line (kindly provided by Dr John Mudgett), was screened with a radiolabeled probe obtained from the PCR fragment described above. Twenty independent Scx mouse genomic clones were isolated and screened with amplified fragments corresponding to the 5 0 and 3 0 end of the cDNA, to identify the ones containing the whole coding region. We decided to focus on clone Scle10. Sequencing was carried out by cycle sequencing in an ABI Prism 377 (Applied Biosystems, Inc.) in both DNA strands by primer walking. Sequence editing and analysis was done with Sequencher 3.0 (Gene Codes Corp., Ann Arbor). The search for transcription factor binding sites was done using MatInspector (Quandt et al., 1995) and TESS (Transcription Element Search Software on the www, Schug, J., Overton, C., 1997 . Technical Report CBIL-TR-1997 .0. Computational Biology and Informatics Laboratory, School of Medicine, University of Pennsylvania, URL:http:// wwwcbil.upenn.edu/tess). Sequence comparison was done using Wisconsin Package version 10.3 (Accelrys, Inc., San Diego, CA).
RNA in situ hybridization analysis
Embryos were harvested at different stages of development, fixed overnight with 4% paraformaldehyde at 4 8C and transferred to 0.5 M sucrose at 4 8C until use. Embryos were then embedded in optimal cutting temperature (OCT) (Tissue-Tek) and stored at 2 70 8C. Frozen sections (12 mm) were cut and transferred to slides. In vitro transcribed 35 S-RNA labeled sense and antisense probes were made using T3 or T7 RNA polymerases. The probe covered 400 bp of the 3 0 -end of the transcribed region of scleraxis and was designed so that there was minimal overlap in the homology between scleraxis and paraxis (Cserjesi et al., 1995) . Hybridization and washes were done as described in Perez-Castro et al. (1993) except that the last 0.1XSSC wash was done at 60 8C. Slides were exposed to X-ray film for three days and then dipped in NTB-2 emulsion (Kodak). Slides were exposed in emulsion for 10 -15 days before being developed and were subsequently examined by dark-field microscopy.
Scleraxis/lacZ transgenic constructs
Several constructs were made (Fig. 4) . The first construct included the whole 11 Kbp of the scx genomic locus with a lacZ reporter gene inserted in frame with the scleraxis gene. To make the total Scx/lacZ full-length construct, a Hinc IISma I fragment, containing 7 Kbp of 5 0 flanking region of the Scx gene and part of the first exon was ligated into the HincII-Sma I sites of pBluescript II SK-vector (Stratagene). The Spe I site present in pBluescript vector had been modified and instead it had an Asc I site. The resulting plasmid, SKA3HS8, was digested with Sma I and it was ligated to a 3.1 Kbp Sma I-Pst I fragment containing a promoterless lacZ gene that had been removed from pMC1871 (Pharmacia). Nucleotide sequencing confirmed that the lacZ gene was in frame with the Scx gene. The resulting clone, SKA3HS8Z11, was digested with Not I and Asc I and it was ligated 5 0 of a 3.3 Kbp Not I-Asc I fragment containing the rest of the first exon, the intron, the second exon and 2.0 Kbp of 3 0 flanking region of the Scx gene. The resulting clone, SKA3SH8Z11NA1, was digested with Xho I and Not I to release the construct from vector sequences before microinjection.
Deletion constructs were made with different fragments of the scleraxis gene and a lacZ gene under the regulation of the HSp68 promoter (Kothary et al., 1989) .
The ZA10 construct was made from a clone named ScHincII-X2XE453 that contained the whole 5 0 flanking region of the scx gene. It was digested with Sal I and ligated to a 4.5 Kbp Sal I fragment that contained the lacZ gene under the control of the Heat Shock p68 promoter. The lacZ gene has its own polyA þ signal (Kothary et al., 1989) .
For the ZBX6 construct, the cloned ScHincII-X2XE453, mentioned above, was digested with Xba I and Xho I releasing a 500 bp fragment that contained 5 0 flanking sequence of the scleraxis gene up to 135 bp before the start of translation. The resulting clone, ScHinc II-X2XE453BX1, was digested with Sal I and ligated to THE 4.5 Kbp Sal I fragment that contained the lacZ gene. The resulting clone, ZBX6, was digested with Not I to release the construct from vector sequences before microinjection.
The Z330 construct was made using a 355 bp PCR fragment amplified using clone ScHincII-X2XE453BX1 as template, a T7 primer and primer XPRI330 5 0 -GCTCTA-GAGTGCACA-TGGAAGGAGAG-3 0 . The following PCR conditions were used: denaturing at 94 8C for 30 s, annealing at 45 8C for 30 s, and elongation at 72 8C for 30 s for a total of 30 cycles. The amplified fragment contained 355 bp of the 5 0 -flanking region of the Scx gene. It was digested with Xba I and Xho I and cloned into pBlueskript II-SK vector. The resulting clone, BX1T7/XPRI330, was digested with Sal I and ligated to the same 4.5 Kbp Sal I fragment used in the BX6/LacZ construct. The resulting clone, ZBX1T7XPRI330, was digested with Not I to release the construct from vector sequences before injection.
For the ZIS129 construct, the ScHinc II-X2XE453BX1 clone was digested with Spe I and religated. The new clone, BX1S2, contained 200 bp of the 5 0 -flanking region of the Scx gene up to 135 bp before the start of translation. The clone BX1S2 was digested with Sal I and ligated to the same 4.5 Kbp Sal I fragment used above. The resulting clone, ZBX1S29, was digested with Not I to release the construct from vector sequences before injection.
All constructs were sequenced at every stage of cloning for verification. The DNA used for injection was cleaned with QIAquick PCR purification kit (QIAGEN).
Generation of transgenic mice and genotyping
Microinjection and oviduct transplantation of injected zygotes were performed as described by Hogan et al. (1986) . Fertilized eggs were obtained from superovulated F 1 (C57BL/6J X DBA/2 J) females impregnated by F 1 (C57BL/6J X DBA/2 J) adult stud males. Pseudopregnant females were produced by matings of CD1 adult females and CD1 vasectomized males. Transferred transgenic F o embryos were isolated at different stages of development or embryos were allowed to go to term to establish transgenic lines.
Genotyping of transgenic mice carrying the full-length Scx/lacZ construct was done by dot blot of genomic DNA isolated from tails or yolk sacs using lacZ as a probe. Three lines were established. Genotypying of transgenic mice carrying all other constructs was done by PCR of genomic DNA isolated from tails or yolk sacs with primers lacZLPF 5 0 -AACTGGAAGTCGCCGCGCCACTGGTGTGGG-3 0 and lacZLPR 5 0 -TGAACTGCCAGCTGGCGCAGGTAG-CAGAGC-3 0 (Ma et al., 2000) . PCR amplification was carried out for 30 cycles with denaturation at 94 8C for 30 s, annealing at 65 8C for 30 s, and elongation at 72 8C for 30 s.
b-galactosidase staining and histology
Embryos were obtained at specific stages of development and fixed in 4% paraformaldehyde for 20 min at 4 8C before staining. Embryos were then washed with 1XPBS (150 mM NaCl, 15 mM sodium phosphate, pH 7.0). Staining for b-galactosidase was done at 37 8C overnight in X-Gal staining solution (2 mM MgCl 2 , 0.01% sodium deoxycholate, 0.02% NP-40, 0.1% 4-chloro-5-bromo-3-indolyl b-galactosidase (X-Gal), 5 mM potasssium ferricyanide, 5 mM potassium ferrocyanide in PBS). After whole-mount lacZ analysis, embryos were post-fixed with 4% paraformaldehyde at 4 8C for 20 min and then washed with PBS. Embryos were switched to 0.5 M sucrose in 1XPBS at 4 8C until they were embedded in OCT for frozen sectioning.
Immunohistochemistry
Frozen embryo sections were immunostained using two different anti-human tenascin polyclonal antiserum HxB-2873 and HxB-1005, kindly provided by Dr H.R. Erickson. These experiments were done using the ABC Vector kit (Vector Laboratories).
Frozen sections from b-galactosidase-stained embryos were immunostained with a primary mouse antibody against anti-skeletal myosin heavy chain (monoclonal anti-skeletal myosin (Fast) clone MY-32) using a Staining Dako ARK kit (DAKO Corporation, Inc., Carpinteria, CA) and following the manufacturer's recommendations. Briefly, sections were dried for 1 h at room temperature, fixed with acetone for 10 min at room temperature, and then air-dried. Sections were washed with 1XPBS for 5 min, blocked with peroxidase for 5 min, and washed again 2 £ for 2 min with 1XPBS. Sections were incubated with the biotinylated antimouse anti-myosin heavy chain primary antibody for 15 min at room temperature, washed 2 £ for 2 min with 1XPBS, incubated for 15 min with Streptavidin -Peroxidase, and again washed 2 £ for 2 min with 1XPBS. After washing, slides were incubated for 5 min with the diaminobenzidine plus substrate-chromogen solution at room temperature. Finally slides were washed 2 £ for 2 min with 1XPBS, dehydrated, counterstained with eosin for 30 s and mounted with Permount.
